Potential Practice-Changer for Refractory Metastatic Colon Cancer Significant survival gain with fruquintinib in patients with heavily pretreated disease Sep 14, 2022
Non-Chemo Regimen Led to High Response Rates in Cisplatin-Ineligible Bladder Cancer "Encouraging activity" with enfortumab vedotin-pembrolizumab in patients with high unmet need Sep 14, 2022
Long-Term ADT With Radiation Helps Prevent Post-Prostatectomy Metastases However, no benefit seen with short-term hormone therapy versus radiotherapy alone Sep 13, 2022
Denosumab Halts Bone Loss From Ovarian Suppression, AIs for Breast Cancer Areal BMD increased when given at the start of maximal estradiol depletion therapy Sep 13, 2022
Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma Large increase in event-free survival with neoadjuvant plus adjuvant versus only adjuvant therapy Sep 13, 2022
KRAS Inhibitor Tops Docetaxel for Previously Treated NSCLC "New second-line standard" in KRAS G12C-mutant disease, says study investigator Sep 13, 2022
Triplet in First-Line Kidney Cancer Thwarts Disease Progression Randomized study shows "clinically meaningful" PFS improvement over dual immunotherapy alone Sep 13, 2022
Survival Bump in Unfit NSCLC With First-Line Immunotherapy Atezolizumab doubles OS at 2 years versus chemotherapy in those ineligible for platinum doublets Sep 12, 2022
Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma Pathologic complete responses seen in 63% of patients in phase II data Sep 12, 2022
Three Adjuvant Immunotherapy Trials Flop in Renal Cell Carcinoma Studies appear to contradict benefit previously shown with pembrolizumab in this setting Sep 12, 2022
Colorectal Cancer Burden on the Rise in Developed Countries Global study predicts an uptick in incidence and mortality through 2040 Sep 12, 2022
Combination Therapy Shows Promise for NSCLC That Progresses on Osimertinib About half of patients responded to tepotinib plus osimertinib, but efficacy ceiling persists Sep 12, 2022
'Striking' Colon Cancer Data Spur Mid-Presentation Ovation at ESMO Preoperative immunotherapy combo in dMMR disease yields major pathologic response in 95% Sep 12, 2022
Tumor Infiltrating Lymphocytes Reemerge as Potential Melanoma Option More than 50% increase in 6-month PFS versus ipilimumab after progression on first-line anti-PD-1 Sep 12, 2022
Add-On Pembrolizumab Misses in Locally Advanced Head and Neck Cancer Post hoc data point to possible benefit in patients with higher PD-L1 levels Sep 11, 2022
Locking Down a Link Between Pollution and EGFR-Mutated Lung NSCLC Study also shed lights on what may lead to lung cancer in never smokers Sep 11, 2022
'Potential New Standard' for Progressing Desmoid Tumors Risk of disease progression or death reduced by 71% with oral gamma secretase inhibitor Sep 10, 2022
Targeted Combo Flops as First-Line Treatment in Advanced Breast Cancer No clinical benefit boost with anti-CD73 oleclumab added to durvalumab and chemo Sep 10, 2022
Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trials Results from SOLO-1 and PAOLA-1 show "clinically meaningful" long-term results with olaparib Sep 09, 2022
Worse OS With Rucaparib First in Trial of Recurrent, BRCA+ Ovarian Cancer A closer look at why PARP inhibitor's third-line indication was withdrawn Sep 09, 2022
Antibody-Drug Conjugate Prolongs Survival in Metastatic Breast Cancer Positive outcome with sacituzumab govitecan leads to questions about ADC sequencing Sep 09, 2022
Robotic Surgery Tops Laparoscopic Surgery for Middle and Low Rectal Cancer Randomized trial shows fewer positive circumferential resection margins with robotic technique Sep 09, 2022
CAR-T Therapy Effective in Youngest Kids With ALL Analysis shows safety and outcomes equivalent to those reported in older children Sep 08, 2022
Study: Microwave Ablation for Lung Nodules Effective as Last Resort Good option for patients who can't have surgery or radiotherapy, surgeon says Sep 08, 2022
Rezvilutamide Bests Bicalutamide in Metastatic Prostate Cancer Combined with ADT, the androgen-receptor inhibitor significantly improved OS, radiographic PFS Sep 07, 2022
Jane Fonda's Non-Hodgkin Lymphoma The award-winning actress opened up about her latest health news Sep 06, 2022
Keytruda Plus T-VEC Falls Short in Unresectable Melanoma No significant survival benefit with combination, but certain patients lived longer Sep 02, 2022
A Light at the End of the Tunnel for Low-Risk Prostate Cancer? The MUSIC model might improve quality of life and prevent overtreatment Sep 02, 2022
10-Year Follow-Up Confirms Benefit of Chemoradiotherapy in MIBC Patients Findings "supported a change in clinical practice" Sep 01, 2022
Does PARP Inhibitor Maintenance Induce Platinum Resistance in Ovarian Cancer? Shorter progression-free interval with platinum chemotherapy after olaparib maintenance Sep 01, 2022
2 Years of Endocrine Therapy, 2 Decades of Protection From Metastatic Breast Cancer Tamoxifen protects low-risk premenopausal patients, goserelin helps high-risk patients Aug 31, 2022
Trainees May Miss More Sessile Serrated Polyps on Colonoscopy But resident or fellow involvement didn't have a negative impact on other key quality indicators Aug 31, 2022
Bispecific Antibody Active in Heavily Treated Multiple Myeloma Responses in 60% of patients who had received a median of five prior lines of therapy Aug 30, 2022
Nonselective Beta-Blockers May Improve Outcomes in Ovarian Cancer Lower all-cause, cancer-specific mortality in women who received the drugs around time of surgery Aug 29, 2022
Pralsetinib Shows Promise in Diverse RET Fusion-Positive Cancers An ORR of 57% supports results previously observed in NSCLC and thyroid cancer Aug 26, 2022
Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomes Overall response rates were 67% with decitabine, 48% with azacitidine Aug 22, 2022
Intensive Endoscopy Might Not Be One-and-Done for Gastric Cancer Surveillance High-risk group had similar new lesion detection rates initially and at 15 months Aug 22, 2022
Florida Oncologist Presumed Lost at Sea The Coast Guard recently suspended its search for Chaundre Cross, MD, of Naples Aug 19, 2022
PK Modulator Shows Promise in Thalassemia In small study, mitapivat increased hemoglobin in 80% of non-transfusion-dependent patients Aug 17, 2022
